Caricamento...
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-opti...
Salvato in:
| Pubblicato in: | Chin J Cancer |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124233/ https://ncbi.nlm.nih.gov/pubmed/27887628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0162-7 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|